The latest price target for Fortress Biotech (NASDAQ:FBIO) was reported by HC Wainwright & Co. on November 18, 2024. The analyst firm set a price target for $26.00 expecting FBIO to rise to within 12 months (a possible 1411.54% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Fortress Biotech (NASDAQ:FBIO) was provided by HC Wainwright & Co., and Fortress Biotech maintained their buy rating.

There is no last upgrade for Fortress Biotech

There is no last downgrade for Fortress Biotech.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fortress Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fortress Biotech was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.

While ratings are subjective and will change, the latest Fortress Biotech (FBIO) rating was a maintained with a price target of $24.00 to $26.00. The current price Fortress Biotech (FBIO) is trading at is $1.72, which is out of the analyst’s predicted range.